Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 3;139(5):792-796.
doi: 10.1182/blood.2021012932.

CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network

Marion Alcantara  1   2 , Caroline Houillier  3 , Marie Blonski  4 , Marie-Thérèse Rubio  5   6 , Lise Willems  7 , Agathe Waultier Rascalou  8 , Magali Le Garff-Tavernier  9 , Karim Maloum  9 , Clotilde Bravetti  9 , Laetitia Souchet  10 , Damien Roos-Weil  10 , Véronique Morel  10 , Madalina Uzunov  10 , Carole Metz  11 , Meriem Dhib-Charfi  11 , Stéphanie Nguyen  10 , Natalia Shor  12 , Dimitri Psimaras  3 , Nicolas Weiss  13 , Nathalie Jacque  10 , Silvia Solorzano  10 , Nicolas Gauthier  10 , Marie Le Cann  10 , Françoise Norol  10 , Carole Soussain  1   2 , Sylvain Choquet  10
Affiliations

CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network

Marion Alcantara et al. Blood. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival and imaging of patients with R/R PCNSL treated with commercial anti-CD19 CAR T-cells. (A) OS and PFS. Median OS was not reached. Median PFS was 122 days for the whole cohort, increasing to 210 days for responders, vs 29 days for non-responders. (B) Patient 3: right frontal lesion at baseline and CR 2 months after CAR T-cell infusion. (C) Illustration of the flare effect suspected in patient 6: appearance of a left periventricular lesion 1 month after CAR T-cell infusion that dramatically decreased 2 and 5 months later. Despite high suspicion of a flare effect, response was reported as progressive disease according to the IPCG criteria, thus potentially underestimating PFS.
See this image and copyright information in PMC

References

    1. Houillier C, Soussain C, Ghesquières H, et al. . Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology. 2020;94(10):e1027-e1039. - PMC - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, et al. . Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544. - PMC - PubMed
    1. Locke FL, Ghobadi A, Jacobson CA, et al. . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42. - PMC - PubMed
    1. Schuster SJ, Bishop MR, Tam CS, et al. ; JULIET Investigators . Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56. - PubMed
    1. Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019;111(7):646-654. - PubMed